AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1778 participants.

Also called NCT07797335

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,778 participants (planned count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07797335
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Brazil, Bulgaria, Canada, China, Czechia, Germany, Greece, India, Italy, Mexico, Poland, Spain, Türkiye, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07797335. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-24 (actual); primary completion 2028-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
Acronym
AMBITION 7
Condition
Cardiovascular Risk
Intervention (Drug)
Zenagamtide
Intervention (Drug)
Insulin glargine U-100
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct07797335
Content hash
744aca3e10969e1315a9afbc684fcb62203cc605bb0dab825a96d268ca8c27b5